Angi Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Angi Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $223.21M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $181.72M | Mar 14, 2018 |
| FY2017 | Jun 30, 2017 | $180.71M | Mar 14, 2018 |
| FY2017 | Mar 31, 2017 | $150.75M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $123.67M | Mar 14, 2018 |
| FY2017 | Sep 30, 2016 | $133.56M | Mar 14, 2018 |
| FY2017 | Jun 30, 2016 | $130.17M | Mar 14, 2018 |
| FY2017 | Mar 31, 2016 | $111.49M | Mar 14, 2018 |
| FY2017 | Dec 31, 2015 | $361.20M | Mar 14, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.19B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.36B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.76B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.62B | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $359.30M | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $389.91M | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | $375.06M | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | $343.65M | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $321.51M | Feb 16, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $983.10M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.13B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.30B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.43B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.34B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.29B | Mar 1, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.41M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $21.89M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($26.50M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | ($75.62M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($67.92M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($4.70M) | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | ($3.02M) | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | $17.64M | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | ($16.30M) | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $6.16M | Feb 16, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.36M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $95.36M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $96.54M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $73.82M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $70.93M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $68.80M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $64.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $61.14M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $47.91M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $20.60M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $27.07M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $6.21M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $188.42M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $214.16M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $223.70M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $41.82M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $47.90M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.60M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $50.49M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $47.78M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $115.48M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $69.91M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $52.49M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $68.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $46.98M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $26.84M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $16.66M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.68B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.83B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.86B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.91B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.01B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.37B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.92B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.81B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $1.47B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $295.52M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.06B | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | $1.04B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.05B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.27B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.31B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.31B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $993.35M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $153.13M | Mar 14, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $890.07M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $883.44M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $886.05M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $882.95M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $916.04M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $891.80M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $883.96M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $894.71M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $770.23M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $170.99M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($150.88M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($195.02M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($231.02M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($190.08M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($61.63M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $9.75M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $16.03M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($18.80M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($121.76M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $303.70M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $416.43M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $364.04M | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $321.16M | Feb 20, 2026 |
| FY2024 | Dec 31, 2021 | $428.14M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $812.71M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $390.57M | Mar 1, 2023 |
| FY2019 | Dec 31, 2018 | $336.98M | Feb 28, 2020 |
| FY2019 | Dec 31, 2017 | $221.52M | Feb 28, 2020 |
| FY2019 | Dec 31, 2016 | $36.38M | Feb 28, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $720.00M | Feb 16, 2021 |
| FY2019 | Dec 31, 2019 | $247.50M | Feb 28, 2020 |
| FY2019 | Dec 31, 2018 | $261.25M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $275.00M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |